Shots:
- The P-III (QUANTI; N=808) trials of gadoquatrane (0.04mmol Gd/kg body wt.) comprised of QUANTI CNS for CNS disorders like brain tumors, brain metastasis & multiple sclerosis; QUANTI OBR for other body regions like head & neck, thorax, abdomen & pelvis as well as QUANTI Pediatric study for children (birth to 18yrs.)
- Study assessed gadoquatrane vs macrocyclic GBCAs (0.1mmol Gd/kg body wt.) & scans without contrast injection for its use in MRI. It achieved all the EPs of visualization & lesion detection, with similar PK profile in children
- Safety aligned with prior data without any new concerns. Bayer will share a comprehensive data package incl. above findings with the regulatory bodies globally for approval
Ref: Bayer | Image: Bayer
Related News:- Bayer Reports the US FDA’s sNDA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
